Relationship Between Changes in Bone Mineral Density and Vertebral Fracture Risk Associated With Risedronate
- 1 September 2004
- journal article
- clinical trial
- Published by Elsevier in Journal of Clinical Densitometry
- Vol. 7 (3) , 255-261
- https://doi.org/10.1385/jcd:7:3:255
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Adverse Outcomes of Osteoporotic Fractures in the General PopulationJournal of Bone and Mineral Research, 2003
- Treatment of postmenopausal osteoporosisThe Lancet, 2002
- Changes in Bone Density and Turnover Explain the Reductions in Incidence of Nonvertebral Fractures that Occur during Treatment with Antiresorptive AgentsJournal of Clinical Endocrinology & Metabolism, 2002
- Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugsThe American Journal of Medicine, 2002
- A method to assess the proportion of treatment effect explained by a surrogate endpointStatistics in Medicine, 2001
- Osteoporosis Prevention, Diagnosis, and TherapyJAMA, 2001
- Antifracture Efficacy of Antiresorptive Agents Are Related to Changes in Bone DensityJournal of Clinical Endocrinology & Metabolism, 2000
- Long-term fracture prediction by bone mineral assessed at different skeletal sitesJournal of Bone and Mineral Research, 1993
- Bone density at various sites for prediction of hip fracturesThe Lancet, 1993
- Pre-Existing Fractures and Bone Mass Predict Vertebral Fracture Incidence in WomenAnnals of Internal Medicine, 1991